Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00790647 · OUTCOME

Number of Participants Surviving at 2 Years

Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis · Source last updated 2017-02-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
2 years from transplant

Groups in this outcome

Stem Cell Transplant With Bortezomib and Melphalan

Mobilization with Filgrastim Stem Cell Collection Bortezomib Melphalan Stem Cell infusion filgrastim: 16 mcg/kg daily beginning 3 days before Stem Cell Collectionthrough day before final Stem Cell Collection bortezomib: 1.0 mg/m2/dose D -6, D-3, D +1, D + 4 melphalan: 100 mg/m2/dose D -2, D -1 Stem Cell Infusion: infusion of previously collected autologous stem cells

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Stem Cell Transplant With Bortezomib and Melphalan9

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Stem Cell Transplant With Bortezomib and Melphalan9Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        9
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    units
    Participants
groups
  1. description
    Mobilization with Filgrastim Stem Cell Collection Bortezomib Melphalan Stem Cell infusion filgrastim: 16 mcg/kg daily beginning 3 days before Stem Cell Collectionthrough day before final Stem Cell Collection bortezomib: 1.0 mg/m2/dose D -6, D-3, D +1, D + 4 melphalan: 100 mg/m2/dose D -2, D -1 Stem Cell Infusion: infusion of previously collected autologous stem cells
    id
    OG000
    title
    Stem Cell Transplant With Bortezomib and Melphalan
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
2 years from transplant
title
Number of Participants Surviving at 2 Years
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice